Kyowa Kirin received FDA approval for Nourianz (istradefylline) as an add-on to treat patients with Parkinson’s disease.

The oral adenosine receptor antagonist is for treatment of adult patients with Parkinson’s experiencing “off episodes” who are already taking levodopa/carbidopa.

The approval was granted based on the results of four clinical trials that included 1,143 patients, which showed that patients treated with Nourianz experienced a statistically significant benefit compared to patients receiving placebo.